Table 3.
Group | HF long (n = 7) | HTx long (n = 7) | P-value |
---|---|---|---|
Age at time of respective study (years) | 47 ± 19 | 48 ± 19 | NA |
Gender n (%) | |||
Male | 5 (71%) | Same | NA |
Female | 2 (29%) | ||
BMI (kg/m2) | 23.4 ± 3.3 | 26.4 ± 4.9 | <0.009 |
Diabetes n (%) | 2 (29%) | 2 (29%) | NA |
Weight gain since HTx (kg) | NA | 9.6 ± 6.2 | NA |
Time since HTx (months) | NA | 7.4 ± 4.4 | NA |
Aetiology | |||
Ischaemic | 1 (14%) | Same | NA |
Dilated | 5 (71%) | ||
Valvular | 1 (14%) | ||
HF drug therapy | |||
Loop diuretic | 7 (100%) | NA | NA |
ACE-inhibitor | 7 (100%) | ||
Beta-blocker | 3 (43%) | ||
Inotropes | 5 (71%) | ||
HTx drug therapy | |||
Prednisone (mg) | NA | 6 ± 4 | NA |
Cyclosporine A | 3 (43%) | ||
Tacrolimus | 4 (57%) | ||
Mycophenolate mofetil | 6 (86%) |
NA, not applicable.
Bold text denotes P ≤ 0.05.